Abstract
Study on Application of Alfacalcidol Soft Capsule Combined with Raloxifene in the Postoperative Treatment of Postmenopausal Osteoporotic Thoracolumbar Fractures
Department of Orthopedics, 1Department of Ultrasound Medicine, 2Medical Equipment Department, Chongqing Qijiang District People’s Hospital, Qijiang, Chongqing 401420, China
Correspondence Address:
Jin Chen, Department of Orthopedics, Chongqing Qijiang District People’s Hospital, Qijiang, Chongqing 401420, China, E-mail: df198347@163.com
To discuss the effect of alfacalcidol soft capsule combined with raloxifene in the postoperative treatment of postmenopausal osteoporotic thoracolumbar fractures. Selected 94 patients with postmenopausal osteoporotic thoracolumbar fractures who underwent percutaneous vertebroplasty in our hospital from January 2019 to January 2021 and then randomly divided them into a control group and a combined group (n=47). After operation, control group received raloxifene tablets treatment, while combined group received alfacalcidol soft capsule and raloxifene tablets treatment. Both groups had no significant difference in scores of Oswestry disability index before drug therapy (p>0.05). After drug therapy, Oswestry disability index scores of both groups were lower than before therapy (p<0.05) and combined group had lower Oswestry disability index scores than control group (p<0.05). After drug therapy, the bone mineral density and bone mineral content of both groups were higher than before therapy (p<0.05) and these in combined group were higher than control group (p<0.05). After drug therapy, the levels of bone gla protein and bone alkaline phosphatase of both groups were higher than those before therapy (p<0.05), while the levels of beta-C-terminal telopeptide and type I procollagen N-terminal peptide of both groups were lower than before therapy (p<0.05) and the levels of bone gla protein and bone alkaline phosphatase in combined group were higher than control group (p<0.05) and the levels of beta-C-terminal telopeptide and type I procollagen N-terminal peptide in combined group were lower than control group (p<0.05). Both groups had no significant difference in adverse reactions rate (p>0.05). The fracture recurrence rate in combined group 1 y after operation was lower than control group (p<0.05). Application of alfacalcidol soft capsule combined with raloxifene in the postoperative treatment of postmenopausal osteoporotic thoracolumbar fractures can improve dysfunction and bone strength, and regulate bone metabolic indexes and reduce fractures recurrence rate with good safety.
